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ABSTRACT 
 
Clostridium difficile Toxin A (TcdA) monoclonal (Mab) and polyclonal (Pab) 
antibodies were produced for use by the USDA-Center for Veterinary Biologics 
(CVB) in anticipation of vaccine product licensing requests. The Virus-Serum-Toxin 
Act which requires potency evaluation of bacterins and toxoids prior to sale is 
implemented by the CVB which produces the reagents necessary for product 
testing. The monoclonal antibody was isotyped and determined to be IgG1, κ. The 
antibodies were also tested using indirect enzyme-linked immunoabsorbent assay 
(ELISA), sandwich ELISA, western blot and toxin neutralization tests to determine 
their neutralizing effects on TcdA. Both the Mab and Pab had neutralizing activity 
against TcdA in mice and they reacted with TcdA in western blots and ELISA. The 
Pab reacted with TcdA in the sandwich ELISA and neutralized the toxin in mice. The 
Pab was also shown to be specific for TcdA in mouse tests because it would not 
neutralize crude C. difficile toxin. Both antibody preparations reacted with native 
(non-denatured) Clostridium sordellii Toxin HT (TcsH) in ELISA.  
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CHAPTER 1. GENERAL INTRODUCTION 
 
Introduction 
Clostridium difficile is the most common nosocomial pathogen of the 
gastrointestinal tract and has increased in frequency over time. Symptoms of C. 
difficile infection include diarrhea, which is usually non-bloody, or colitis associated 
with severe abdominal pain, fever and/or gross or occult blood in stools. C. difficile 
produces several virulence factors including toxin A (TcdA), toxin B (TcdB), tissue-
degrading enzymes (proteases, collagenase, hyaluronidase, heparinase and 
chondroitin-4-sulfatase) and fimbriae. The two major virulence factors are TcdA, a 
potent enterotoxin and cytotoxin, and TcdB, a potent cytotoxin and mild enterotoxin. 
The toxins are co-produced, are important in pathogenesis and are usually found in 
patients with C. difficile – associated pseudomembranous colitis (PMC) [13]. 
Clostridium sordellii lethal toxin (TcsL) and hemorrhagic toxin (TcsH) have 
often been compared to TcdA and TcdB of C. difficile. The biological and antigenic 
properties of TcdA and TcdB are very similar to those of TcsH and TcsL, 
respectively [3]. 
Clostridium sordellii is a species of anaerobic, spore forming bacteria that is 
the etiologic agent of clostridial myonecrosis (gas gangrene) in humans as well as 
domestic animals. It can also cause enterotoxemia in cattle and sheep [1-3]. The 
pathogenesis of the disease is due to two separate toxins, TcsL and TcsH [3]. 
Although there are common preventative vaccines used for C. sordellii, it is unknown 
if these vaccines protect against both TcsL and TcsH. 
Results from an experiment in which guinea pigs vaccinated with toxoids 
containing toxoided TcsL, TcsH, or both TcsL/TcsH were challenged with virulent 
strains of C. sordellii that expressed both TcsL and TcsH toxins indicated that 
animals may need immunity to both the lethal and hemorrhagic toxins to be 
completely protected from C. sordellii because both are essential protective antigens 
[3]. Currently, it is unknown whether currently licensed animal vaccines confer 
protection against both toxins because the vaccine potency test requirement only 
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requires that the vaccines protect against TcsL. By developing a test to measure the 
potency of current vaccines against TcsH, I will be able to ascertain whether or not 
the vaccinated animals are protected against both toxins of C. sordellii. 
Recent studies have shown that TcsH toxoid may play a considerable role in 
protection against challenge spores of TcsH – expressing C. sordellii strains [3]. The 
goals of the research contained in this dissertation are 1) produce reagents to test 
currently licensed vaccines to determine if they elicit anti-HT antibodies in 
vaccinated animals, and 2) Clone the TcsH gene to facilitate the development of 
molecular diagnostics and the producton of highly purified reagents. Hopefully this 
research will lead to development of more appropriate regulatory tests to determine 
if better vaccines are needed that are capable of protecting against both TcsL and 
TcsH. 
 
 
Literature Review 
Clostridium difficile is the most common nosocomial pathogen of the 
gastrointestinal tract and has increased in frequency over time. Symptoms of C. 
difficile infection include diarrhea, which is usually non-bloody, or colitis associated 
with severe abdominal pain, fever and/or gross or occult blood in stools. 
Pseudomembranous colitis (PMC) in humans and antibiotic-associated colitis (AAC) 
in experimental animals is the most severe form that results from a severe 
inflammatory response to C. difficile toxins [13, 14]. The disease has been 
diagnosed in domestic and wild animals including: Kodiak bear, penguin, captive 
ostriches, rabbits, hares and adult horses. C. difficile has been found in the gut of 
dogs and pups with chronic diarrhea. It has also been isolated from camels, 
donkeys, swine and cats [6]. C. difficile causes AAC in experimental laboratory 
animals, including hamsters, mice, guinea pigs, rabbits and rats. The disease 
progresses rapidly to cecitis and hemorrhage, ulceration and inflammation are 
evident in the intestinal mucosa. The animals become lethargic and develop severe 
diarrhea, and a high percentage of the animals die from the disease [15]. 
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Clostridium difficile is an anaerobic bacterium that was first isolated from 
normal microbial flora in the stool of infants. It has also been isolated from other 
sources, including wounds; war wounds; superficial infections; various human 
pathological specimens such as pus and other exudates; tissues exhibiting gas 
gangrene; abscesses; blood culture; pleural fluid; peritoneal fluid and the intestinal 
tract of Wendell seals [1]. C. difficile is unique in that the affected hosts have nearly 
always been exposed to antimicrobials. Clindamycin – associated PMC has been 
repeatedly documented. Hospitalization is considered a major risk of acquiring PMC 
due to the exposure of patients to a concentrated source of the pathogen. The 
length of stay increases the risk of infection [6]. 
Clostridium difficile is a sporulating gram positive anaerobic bacterium that is 
6-8 microns in length and 0.5 microns in width. The spores are oval, terminal and 
don’t cause swelling in the rods. The gram positive characteristic can be lost after 
one day of incubation [1]. C. difficile produces several virulence factors including 
toxin A (TcdA), toxin B (TcdB), tissue-degrading enzymes (proteases, collagenase, 
hyaluronidase, heparinase and chondroitin-4-sulfatase) and fimbriae. The two major 
virulence factors are TcdA, a potent enterotoxin and cytotoxin, and TcdB, a potent 
cytotoxin and mild enterotoxin. The toxins are co-produced, are important in 
pathogenesis and are usually found in patients with C. difficile – associated PMC 
[13]. 
Severity of the disease, caused by C. difficile, ranges from benign diarrhea to 
PMC [13]. PMC is a serious colonic disease which can occur when antibiotics or 
other agents disrupt the normal flora. The disease rarely occurs without prior 
antibiotic therapy [17]. PMC is usually associated with watery diarrhea, fever, 
abdominal cramping and leukocytosis. These symptoms can occur after 4 days of 
antibiotic treatment, but may occur up to 6 weeks after antibiotics have been 
discontinued. PMC was first recognized as a manifestation of C. difficile infection 
and thought to be a side effect of clindamycin therapy. PMC results from the 
overgrowth of the large bowel by C. difficile usually after perturbation in bowel flora, 
caused by antibiotic therapy. An identical disease occurs in hamsters and guinea 
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pigs after antibiotic treatment [6]. Although the disease can occur in association with 
any antibiotic, it occurs most commonly with the use of penicillin, ampicillin, 
clindamycin and cephalosporin. Although PMC is most common in adults, especially 
elderly patients; there have been infrequent reports of pediatric PMC [13]. 
The pathophysiology of PMC may involve up to four distinct pathways. The 
first is the disruption of the normal intestinal micro flora by the inducing antibiotic or 
agent. The normal intestinal flora possesses ‘colonization resistance’ or the ability to 
resist the overgrowth of opportunistic pathogens through a variety of mechanisms, 
which include competition for nutrients, production of bacteriocins or toxin degrading 
proteases and receptor site competition. Broad spectrum antibiotics have a greater 
impact on normal flora and are associated with higher rates of intestinal disease 
[13]. 
The second mechanism is cellular distortion and subsequent diarrhea as a 
result of toxins produced by the pathogens. The actions of TcdA and TcdB are 
bimodal; one disrupting the cell cytoskeleton and the other involving the activation of 
the signal transduction pathways of the immune system. TcdA and TcdB are 
produced by C. difficile in the lumen during infection and bind to receptor sites on the 
surface of enterocytes and are then internalized by endocytosis. The toxins 
inactivate guanine-nucleotide-binding protein called rho A, leading to the 
disaggregation of F actin. Rho is involved in maintaining the cytoskeleton structure 
within the cell. Cytoskeleton disruption results in cell rounding which widens the tight 
junctions between enterocytes leading to fluid loss and diarrhea. The tissue damage 
by TcdA results in viscous hemorrhagic fluid response [13]. 
The third mechanism of PMC is the activation of components in the immune 
system. TcdA and TcdB cause mast cell degranulation, up-regulation of leukocyte 
adhesion and release of cytokines from granulocytes. TcdA attracts neutrophils and 
both toxins stimulate the release of cytokines, such as interleukin (IL) 1, IL-6, IL-8 
and tumor necrosis factor from human monocytes. Both toxins act on mast cells to 
release histamine and may affect leukocyte, endothelial cell and platelet interactions 
through up-regulation of certain adhesion molecules [13]. Significant increases in 
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leukocyte adherence and emigration (LAE) and albumin leakage was noted with 
TcdA exposure. This response was accompanied by mast cell degranulation and the 
formation of platelet-leukocyte aggregates. TcdA induced increases in LAE and 
albumin leakage were significantly attenuated by pretreatment with either 
monoclonal antibodies directed against the leukocyte adhesion glycoproteins, 
CD11/CD18, intercellular adhesion molecule-1(ICAM-1) and P-selectin or with sialyl 
Lewis X, a counter receptor for P-selectin. These observations indicate that TcdA 
induces a leukocyte-dependent leakage of albumin from postcapillary venules. Mast 
cell-derived histamine appears to mediate at least part of the leukocyte-endothelial 
cell adhesion and platelet-leukocyte aggregation by engaging H1-receptors on 
endothelial cells and platelets to increase the expression of P-selectin. The adhesion 
glycoproteins CD11/CD18 and the ICAM-1 also contribute to the inflammatory 
responses elicited by TcdA [24]. The profuse release of leukocytes, mucin, fibrin and 
cellular debris results in the formation of a pseudomembrane [13].   
The fourth mechanism may involve the enteric nervous system. TcdA has 
been found to increase myoelectric activity before causing mucosal damage in rabbit 
colonic loop models. The involvement with the enteric nervous system and intestinal 
disease requires further study [13]. 
PMC is diagnosed by assessing the patient on three levels: clinical 
evaluation, stool assays for enteric pathogens and visualization of the colonic 
mucosa. A history of antibiotic use, recent hospitalization, intestinal surgery or 
residence in a chronic care facility may all predispose to PMC. Symptoms of watery 
diarrhea, abdominal pain or cramping and fever are typical. The ‘gold standard’ for 
C. difficile detection is the tissue culture assay for TcdB. The diagnosis of PMC 
includes the detection of C. difficile in the stool. Tests for detection of C. difficile 
include enzyme immunoassays, tissue culture assays and latex agglutination 
assays. C. difficile can also be detected by microbial cultures in the stool. The third 
level of diagnosis is colonoscopic or sigmoidoscopic visualization of 
pseudomembranes [13]. 
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The initial evaluation should assess the level of hydration and severity of 
illness. The two most commonly used antibiotics to treat C. difficile infections are 
metronidazole and vancomycin. Recent recommendations from the Center for 
Disease Control strongly suggest the use of metronidazole as the first line drug of 
choice. The bile-salt-binding resin cholestyramine has also been used to treat C. 
difficile disease. The usual response to therapy is improvement in diarrhea within 1-4 
days with resolution by 2 weeks [13]. 
Both TcdA and TcdB are believed to be involved in the pathogenesis of PMC. 
This is based on findings that (i) both toxins are tissue damaging and lethal when 
injected into animals (ii) experimental animals must be vaccinated against both 
toxins to be protected against the disease and (iii) both toxins are present in fecal 
specimens from patients with PMC [16]. 
In addition to humans, C. difficile can be found in the intestinal tracts of a 
variety of animal species, including food animals, such as pigs and cattle. C. difficile 
has also been found in retail meat. Concern about the role of food in epidemiology of 
community-associated C. difficile infection (CA-CDI) has been expressed [23]. So far 
it is not clear if these animals are a possible source of human C. difficile infections 
[21]. 
Clostridium difficile is well accepted as the etiological agent of C. difficile-
associated disease (CDAD) in neonatal pigs and may contribute to enteritis in calves 
[19, 20]. Infected herds may experience morbidity as high as 97% and while most 
piglets recover, the mortality rate in some outbreaks may be as high as 16% [19]. 
Pseudomembranous colitis and large numbers of C. difficile were 
subsequently described in conventional pigs with naturally occurring CDAD. C. 
difficile and its toxins were detected in an outbreak of CDAD in pigs approximately 5 
days of age; affected piglets were dyspneic, and had mildly distended abdomens, 
scrotal edema, diarrhea, ascites (>50ml), edema of the ascending mesocolon, and 
hydrothorax. Microscopically the distinctive lesions were severe ascending colonic 
submucosal and mesocolonic edema, with multifocal exudation of mucus, fibrin, and 
polymorphonuclear leukocytes (PMN) aggregates. Based upon examination of 
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approximately 2000 individual diseased piglets, the case definition for porcine CDAD 
includes piglets 1 to 7 days of age with a history of scouring since shortly after birth. 
Litters from both gilts and sows are affected. Gross lesions usually include 
moderate-to-severe edema of the mesocolon, and colonic serosal edema is 
common; pseudomembranous formation is uncommon, and the yellow plaques seen 
in human disease are not observed in affected piglets. Colonic contents are 
frequently pasty-to-watery and yellow, although some piglets are constipated or 
obstipated [22]. 
Clinically relevant strains of C. difficile usually produce toxins TcdA and TcdB, 
although C. difficile and its toxins can be found in non-diarrheic piglets. In one such 
group, 74% were TcdA/B positive, but had normal feces or were constipated. It is 
common to find typical lesions in these non-diarrheic piglets. Some piglets present 
with systemic signs, including mild depression, lack of appetite, cachexia and 
anorexia, without diarrhea. Most recover quickly. The only diagnostic findings are the 
toxins in cecum and colon and typhlocolitis consistent with CDAD [22]. 
As with human CDAD, diagnosis of porcine CDAD is based primarily upon 
detection of TcdA/B in stools or intestinal contents. Antibodies against TcdA prevent 
binding, eliminate secretion and inflammation, and prevent clinical disease in mice 
and hamsters; anti-TcdB antibodies also have a role in protection against CDAD. 
Active or passive immunization against TcdA prevents clinical disease. Thus, it may 
be that if a toxin-neutralizing response can be generated in sows, piglets can be 
passively protected by antibodies obtained from colostrum [22]. 
Clostridium sordellii toxins have often been compared to TcdA and TcdB of C. 
difficile. The biological and antigenic properties of TcdA and TcdB are very similar to 
those of TcsH and TcsL, respectively [3]. 
Clostridium sordellii is an anaerobic bacterium that causes clostridial 
myonecrosis (gas gangrene) in humans, as well as, domestic animals. It has also 
been recognized as a causal agent of diarrhea, enterotoxemia and enteritis in cattle 
and sheep [1-3]. It is an important veterinary pathogen that causes bloat, 
hemorrhage, ulcers, liver disease, fatal myositis and sudden death in sheep, cattle, 
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and horses. C. sordellii has also been reported in human maternal deaths with a 
disease resembling toxic shock-like syndrome. The etiology of C. sordellii is poorly 
understood. Myonecrosis is rather infrequent, and death may be due to septicemia, 
as well as the expression of several exotoxins [4, 7]. C. sordellii is pathogenic for 
man, cattle, sheep and laboratory animals. Death can be attributed to the lethal and 
hemorrhagic toxins [1, 3]. The symptoms generally resemble those produced by C. 
novyi because of the marked edema that occurs. This edema is blood-tinged or 
rose-colored instead of being colorless, as with Clostridium novyi. In guinea pigs; 
postmortem, the most pronounced symptom is a subcutaneous, gelatinous edema, 
usually rose-colored, lying between the abdominal muscles and the skin. The 
muscles are red and either uniformly hemorrhagic or discolored by hemorrhagic 
streaks. Gas is also normally evident at site of inoculation. C. sordellii is sometimes 
responsible for liver infections in cattle and sheep. Infection seems to be initiated by 
the liver fluke because the primary lesion is adjacent to the necrotic track left behind 
by the fluke burrowing through the liver [1]. 
The bacterium, initially described as Bacillus oedematis sporogenes by 
Sordelli in 1922, was isolated from cases of acute edematous wound infections in 
South America. In 1927 Hall and Scott suggested the name Bacillus sordellii after 
further study. Meleny et al isolated the same organism, originating from infected 
surgical material, from cases of postoperative infection in a man in 1928. Unaware 
that it was the identical strain as that named by Hall and Scott they named it 
Clostridium oedematiodes. As more strains were studied it was found that C. 
sordellii closely resembled Clostridium bifermentans, but that the C. sordellii isolates 
were simply the pathogenic strains. Tataki and Huet concluded that they were two 
distinct species in 1953. C. sordellii can now be distinguished from C. bifermentans 
by its ability to produce urease and by its characteristic spore antigen [1]. 
Clostridium sordellii habitats in nature have not been clearly established. The 
principal habitat seems to be soil and not the animal body because of the differences 
in the incidence of infection caused by it in many different parts of the world. Cases 
are most often found in the western United States, Latin America, and in Asia Minor; 
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all areas of relatively low rainfall. They are uncommon in Great Britain and the rest of 
Europe [1]. 
Clostridium sordellii is a gram positive sporulating rod and an obligate 
anaerobe [1, 5]. The bacterium is 2-4 microns long and 0.6-1 micron in diameter. 
Spores are sub-terminal to central in position and oval to cylindrical in shape.  
Cultures 3 days old or more will be found to be chalky white and composed almost 
entirely free of spores [1]. 
It appears that all strains of C. sordellii share some antigens, but it is not 
certain that all strains are identical in antigenic structure. Agglutination tests, 
however, cannot be used to definitively distinguish between C. sordellii and C. 
bifermentans. Studies have shown that there are three soluble antigens that are 
common to strains of C. sordellii and are not produced by strains of C. bifermentans 
[1]. 
Clostridium sordellii is one of the causative agents of gas gangrene. It 
produces more edema and induration of the local lesion and less gas than other 
Clostridial species. The incubation period for clostridial myositis may vary from 18 
hours to 6 days [9]. 
All ages and species of animals are affected. In most cases a wound is the 
portal of entry and a dirty environment which permits contamination of wounds with 
soil is the common predisposing cause. The infection is usually soil-borne and the 
resistance of spores of the causative clostridia to environmental influence leads to 
persistence of the infection for long periods in a local area. Potent toxins are 
produced in the local lesion and cause death when absorbed into the bloodstream. 
Locally the exotoxins cause extensive edema and necrosis followed by gangrene 
[11]. 
The local lesion differs from that in the usual type of pyogenic infection. In gas 
gangrene, erythema is not the most conspicuous finding; rather signs of circulatory 
inadequacy are present, due to the rapid formation of edema and gas. The wound 
does not discharge pus, but brownish watery exudates [9]. 
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During the next phase the skin becomes discolored, the lesion taking on a 
reddish-brown tint. This discoloration progresses rapidly in a cranial direction. 
Complete cutaneous necrosis is observed at the wound edges, usually indicating a 
deeper-seated myonecrosis [9]. 
During this phase the “gas boundary” may advance ahead of the causative 
lesion. In gas gangrene caused by C. sordellii formation of gas may be a less 
prominent feature. This variation is frequently recognized too late or not at all. This 
indicates the inadequacy of crepitation due to gas in establishing an early diagnosis 
[9]. 
Clostridium sordellii infection presents with unique clinical features including 
edema, absence of fever, leukemoid reaction, hemoconcentration, and later shock 
and multi-organ failure in humans. Often infections develop after childbirth or after 
gynecological procedures, and most represent endometrial infection. Rarely, cases 
have occurred at sites of minor trauma such as lacerations of the soft tissues of an 
extremity. The absence of fever and the lack of signs or symptoms delay diagnosis. 
The elaboration of a potent toxin is related to the mechanisms of diffuse capillary 
leak, massive edema and hemoconcentration [8]. 
The clinical diagnosis is based on typical signs and lesions. Rapid spreading 
crepitus painful swelling around a wound in a febrile animal is significantly important. 
The presence of gaseous serosanguineous fluid in and around necrotic tissue as is 
revealed by an incision of swollen tissue and at necropsy is additional evidence of 
malignant edema [10].There are also other symptoms and signs. Pain is a prominent 
symptom. It is usually extremely acute, probably due to the rapid occurrence of 
swelling due to edema and gas formation. Hypotension can be a sign at serious 
degrees of toxicity. A psychiatric-neurologic complex of symptoms is also one of the 
toxic manifestations of gas gangrene [9]. When C. sordellii is the causative agent for 
gas gangrene a foul, putrid odor is often present in infections at necropsy [11]. 
Since malignant edema is associated with wound contamination it can be 
partially prevented by minimizing opportunities for injuries in a feedlot. Protruding 
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nails, wire or other sharp objects should be removed from fences and walking areas. 
Vaccination of young cattle gives some protection [10]. 
In early stages of disease it can be treated daily with penicillin at a rate of 
2,000-4,000 units per pound of body weight. After suppression or elimination of 
infection the necrotic tissue should be incised to provide drainage and to accelerate 
healing [10]. 
Clostridium sordellii produces two toxins. The pathogenic C. sordellii strains 
produce lethal toxin (TcsL) alone or both TcsL and hemorrhagic toxin (TcsH). TcsL 
has edematizing and cytotoxic activities in addition to its lethal toxicity. TcsH has 
much weaker lethal and cytotoxic activities than TcsL. Immunizing guinea pigs with 
toxoid containing TcsL, TcsH and both TcsL/TcsH has shown that only the 
TcsL/TcsH toxoid gave complete protection against bacterial challenge with strains 
of C. sordellii. The result shows that TcsL toxoid, as well as, TcsH toxoid are 
essential protective antigens of C. sordellii [3]. 
Clostridium sordellii antitoxin cross-neutralizes TcdA and TcdB of C. difficile. 
This suggests the two toxins of C. sordellii are immunologically related to the C. 
difficile toxins. Intradermal injections of cell-free extracts into guinea pigs caused 
edema and hemorrhage shown to be the result of two separate toxins, the toxin 
causing edema being the more lethal TcsL than the hemorrhagic TcsH. The toxins 
have been separated by ion-exchange chromatography and are usually large. The 
MW for TcsH is 300,000 and TcsL is 260,000 [12]. Purification of TcsH by 
ultrafiltration and immuno-affinity chromatography with a monoclonal antibody (MAb) 
to TcdA can be used as well [7]. 
Clostridium difficile toxin A, a large protein of 308,000 MW, binds to human 
carbohydrate antigens I, X and Y on human epithelial surfaces, but its exact 
intestinal receptor sites in humans are unknown. Clostridium difficile toxin B, a large 
protein of 270,000 MW, is heat labile, and its receptor site has not been identified in 
either humans or animals [13]. A number of methods have been developed for 
purification of TcdA and TcdB. The toxins can be separated by anion exchange 
chromatography and affinity chromatography [12]. TcsH and TcsL are related to 
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TcdA and TcdB, respectively, and are responsible for refractory shock observed in 
some animal and human infections [1, 3, 5]. 
Clostridium sordellii Toxin HT has biological activities and immunological 
properties similar to TcdA.  TcdA has been cloned and sequenced [18]. TcsH is also 
cytotoxic and lethal with minimum doses similar to those reported for TcdA [12]. The 
N-terminal amino acid sequence of TcdA and TcsH also share close identity (Figure 
A [7]. The lethal toxin of C. sordellii is immunologically related to TcdB. However, 
TcdB is 10,000 times more cytotoxic than the TcsL. In contrast, TcsL is tenfold more 
lethal than TcdB. The genes for TcsL and TcdB have been cloned and sequenced 
[12]. See table A for comparison of the four different toxins.   
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A Ser Leu Ile Ser Lys  Glu  Glu  Leu  Ile  Lys  Leu  Ala  Tyr  Ser  Ile  Arg  Pro 
HT Ser Leu Ile Ser Lys  Ser  Glu  Leu  Ile  Lys  Leu  Ala  Tyr  Ser  Ile  Lys  Pro 
 
Figure A. Amino-terminal sequences of Clostridium difficile TcdA and Clostridium sordellii 
TcsH. 
 
 
Clostridium sordellii Clostridium difficile 
Lethal Toxin  (TcsL) Hemorrhagic Toxin 
(TcsH) 
Toxin B (TcdB) Toxin A (TcdA) 
 
MW 260,000 
 
MW 300,000 
 
MW 270,000 
 
MW 308,000 
Similar to TcdB Similar to TcdA Similar to TcsL Similar to TcsH 
Has been sequenced and 
nucleotide sequence 
reveals 76% identity and 
90% homology to TcdB 
 
Not sequenced 
Has been sequenced 
and nucleotide 
sequence reveals 76% 
identity and 90% 
homology to TcsL 
 
Sequenced 
Edematization, cytotoxic 
activities and lethal 
toxicity 
Weaker lethal and 
cytotoxic activities 
than TcsL  
Potent cytotoxin and 
mild enterotoxin 
Potent Enterotoxin and 
Cytotoxin 
Antibodies cross neutralize C. difficile Antibodies cross neutralize C. sordellii 
10 fold more lethal than 
TcdB 
Similar cytotoxicity 
and lethality to TcdA 
10,000 times more 
cytotoxic than TcsL 
Similar cytotoxicity and 
lethality to TcsH 
 
Table A. Comparison of C. sordellii and C. difficile toxins.  
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CHAPTER 2. PRODUCTION AND TESTING OF CLOSTRIDIUM DIFFICILE TOXIN 
A MONOCLONAL ANTIBODY (αCdA Bella-1) AND TOXIN A SPECIFIC 
POLYCLONAL ANTIBODY (IRP 583) 
 
An unsubmitted paper 
 
Teri L. Thiele 
 
Abstract 
Clostridium difficile Toxin A (TcdA) monoclonal and polyclonal antibodies 
were produced for use by the USDA-Center for Veterinary Biologics (CVB) in 
anticipation of vaccine product licensing requests. The Virus-Serum-Toxin Act which 
requires potency evaluation of bacterins prior to sale is implemented by the CVB 
which makes the production of reagents necessary for product testing. The 
monoclonal antibody was isotyped and determined to be IgG1, κ. The antibodies 
were also tested using indirect enzyme-linked immunosorbent assay (ELISA), 
sandwich ELISA, western blot and toxin neutralization tests to check for the 
neutralizing effects they had on TcdA. Both the Mab and Pab had neutralizing 
activity against TcdA in mice and they reacted with TcdA in western blots and 
ELISA. The Pab reacted with TcdA in the sandwich ELISA and neutralized the toxin 
in mice. The Pab was also shown to be specific for TcdA in mouse tests because it 
would not neutralize crude C. difficile toxin which contained TcdB as well. Both 
antisera reacted with native (non-denatured) Clostridium sordellii toxin HT (TcsH) in 
ELISA.  
 
Keywords 
Clostridium difficile; Toxin A (TcdA); Monoclonal antibody 
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1. Introduction 
Clostridium difficile is a sporulating gram positive anaerobe and is the most 
common nosocomial pathogen of the gastrointestinal tract and has a high rate of 
occurrence. Symptoms of C. difficile infection include diarrhea, which is usually non-
bloody, or colitis associated with severe abdominal pain, fever and/or gross or occult 
blood in stools. Pseudomembranous colitis (PMC) in humans is the most severe 
manifestation that results from a severe inflammatory response to C. difficile toxins 
[1, 13, 14]. 
Clostridium difficile has recently emerged as a pathogen or commensal in 
food animals such as neonatal pigs and dairy and beef calves; most of these animal 
isolates are toxigenic [2]. C. difficile causes enteritis in neonatal pigs and calves and 
is the etiologic agent of C. difficile-associated disease (CDAD) in neonatal pigs [1, 3, 
4]. Infected herds may experience morbidity as high as 97% and while most piglets 
recover, the mortality rate in some outbreaks may be as high as 16% [1]. The 
symptoms of porcine CDAD include piglets 1 to 7 days of age with a history of 
scouring since shortly after birth. Gross lesions usually include moderate-to-severe 
edema of the mesocolon, and colonic serosal edema is common; 
pseudomembranous formation is uncommon, and the yellow plaques seen in human 
disease are not observed in affected piglets. Colonic contents are frequently pasty-
to-watery and yellow, although some piglets are constipated or obstipated [4]. 
Clostridium difficile and its toxins can also be found in non-diarrheic piglets. In 
one such group, 74% were TcdA/B positive, but had normal feces or were 
constipated. It is common to find typical lesions in these non-diarrheic piglets. Some 
piglets present with systemic signs, including mild depression, lack of appetite, 
cachexia, and anorexia, without diarrhea. Most recover quickly. The only diagnostic 
findings are the toxins in cecum and colon and typhlocolitis consistent with CDAD. 
Clinically relevant strains of C. difficile usually produce toxins A and B and 
comprehensive diagnosis of porcine CDAD includes clinical history, gross and 
microscopic pathology, bacteriologic culture, detection of TcdA and/or TcdB in feces 
or colonic contents. Toxin detection is the primary confirmatory CDAD diagnostic 
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test for specimens obtained ante mortem or postmortem [4, 1]. Antibodies to TcdA 
have been shown to eliminate binding, secretion and inflammation, and prevent 
clinical disease in mice and hamsters; anti-TcdB antibodies also have a role in 
protection against CDAD. Active or passive immunization against TcdA prevents 
clinical disease. Thus, it may be that if a toxin-neutralizing response can be 
generated in sows, piglets can be passively protected by antibodies obtained from 
colostrum [4]. 
Clostridium difficile has also been found in retail meat resulting in concerns 
about the role of food in epidemiology of community-associated C. difficile infection 
(CA-CDI) [5]. So far it is not clear if food animals are a possible source of human C. 
difficile infections, although there is a high level of overlap between C. difficile types 
present in humans and animals. Two ribotypes associated with outbreaks of severe 
disease in humans have been found in animals also. Modes of transmission 
between human and animal reservoirs could be retail meat, dog food and contact 
with the hospital environment [3]. The goals of the research contained in this study 
are to produce reagents to test the effectiveness of current and/or future licensed 
vaccines. 
 
2. Materials and Methods 
2.1 Bacterial Strain and Culture Filtrates. 
Clostridium difficile strain VPI 10463 (received from Dr. Glenn Songer, 
University of Arizona) Clostridium sordellii VPI 9048 (received from Dr. Robert 
Carman at TechLab, Inc.), and Clostridium sordellii #7502 (CVB strain obtained from 
Dr. Bairey, Jensen-Salsbury Laboratories, Montana) was grown in brain heart 
infusion media in 1-liter dialysis flasks for 24 hours at 37oC. After 24 hours the 
growth in the dialysis bag was collected and centrifuged at 7,300 x g for 60 minutes. 
Prior to filtration Protease Inhibitor (Sigma Co., St. Louis, MO) was added to the 
culture filtrate. Culture supernatant was filtered through a 0.22-µm Millipore Sterivex 
filter. C. difficile strain VPI 10463 expresses TcdA and TcdB, C. sordellii Strain VPI 
9048 expresses HT and LT, and C. sordellii strain #7502 expresses LT but not HT. 
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Toxin expression was determined using a monoclonal antibody kit that detects the 
presence of TcdA (BioStar OIA CdTOX A from Inverness Medical-BioStar Inc., 
Louisville, CO).  
 
2.2 Preparation of immobilized thyroglobulin. 
Bovine thyroglobulin (Sigma Co., St. Louis, MO) was dissolved in coupling 
buffer at a concentration of 10 mg/mL using AminoLink Coupling gel (Thermo Fisher 
Scientific Inc., Rockford, IL) and allowed to incubate overnight at 4oC. The remaining 
active sites on the gel were blocked with quenching buffer (1 M Tris/HCl) and 
cyanoborohydride solution (1 M NaCNBH3 in 0.01 N NaOH) for 30 minutes. The 
column was then washed with 5 bed volumes of 1 M NaCl, to ensure that free 
thyroglobulin did not remain ionically bound to the gel. The immobilized thyroglobulin 
was then used to purify TcdA from C. difficile VPI 10463. 
 
2.3 Affinity Chromatography. 
TcdA was purified from culture filtrates of C. difficile VPI 10463 as previously 
described [6]. The resulting concentration of TcdA was 57µg/mL. 
 
2.4 Production of monoclonal antibody (Mab). 
(i) Preparation of TcdA toxoid. The purified toxin was inactivated with 
0.1% formalin and 20% aluminum hydroxide was added prior to immunization. A 
commercially available toxoid was also used (List Biological Laboratories Inc., 
Campbell, CA). 
(ii) Immunization. BALB/c mice (Harlan Sprague Dawley, Indianapolis, 
IN) were injected subcutaneously with 0.4 mL of toxoid with adjuvant. Two more 
injections of 0.2 mL toxoid with adjuvant were given; each 14 days apart. Each 
animal received a 0.2 mL injection intravenously of purified TcdA toxoid without 
adjuvant 3 to 4 days before splenectomy. 
(iii) Fusion. Spleen cells from immunized mice were fused with Sp2/0 cells 
using the polyethylene glycol method. Hybrid cell lines were selected and their 
20 
 
culture supernatant was analyzed for TcdA antibody by screening ELISA described 
below. Hybrid cells that were positive for TcdA were expanded and subcloned as 
described [7]. 
(iv) Production of ascites fluid. About 2.0 x 106 cells/mouse of the 
selected clones were injected intraperitoneally into BALB/c mice (Harlan Sprague 
Dawley, Indianapolis, IN) primed with pristane (Sigma Co., St. Louis, MO). The 
ascites fluid was clarified by centrifugation, filtered through a 0.45µm membrane, 
labeled αCdA Bella-1 and stored at 4oC. 
 
2.5 Production of TcdA specific polyclonal antibody (Pab). 
A male goat was injected with TcdA toxoid mixed with 2.0 mg/ml of 
Rehydrogel L.V. (Reheis Inc., Berkeley Heights, NJ).  The goat received 1.0 ml 
injections subcutaneously every two weeks for 14 weeks; it was then injected with 
0.5 ml of a commercial TcdA (List Biological Laboratories Inc., Campbell, CA). 
Seven days later blood was collected totaling 4.0 ml/lb of body weight. An additional 
injection with 0.5 ml of a commercial TcdA (List Biological Laboratories Inc., 
Campbell, CA) was given and blood was collected again totaling 4.0 ml/lb of body 
weight. The blood was centrifuged and filtered through bottle top 0.45 µm membrane 
filters, labeled as IRP 583 and stored at 4oC. 
 
2.6 ELISAs 
(i) Screening ELISA. A screening ELISA was performed on supernatant 
from all wells containing hybridoma cells. Microtiter plates were coated with the 
appropriate amount of antigen in carbonate buffer (pH 9.6). The plates were 
incubated for 1 hour ± 15 minutes at 37oC then washed four times with 0.01 M 
phosphate buffered saline (PBS) with 0.05% polyethylene glycol sorbitan 
monolaurate (Tween 20). The plates were then blocked for 1 hour ± 15 minutes at 
37oC with blocking solution 0.01 M PBS with 2% Non-fat dry milk (NFDM). Tissue 
culture supernatant from each hybridoma (producing clusters) was added to each 
well of the test plate diluted 1:1 in blocking solution and incubated for 1 hour ± 15 
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minutes at 37oC.  The plates were washed 4 times with 0.01 M PBS with 0.05% 
Tween 20 and 0.1 mL of affinity purified antibody peroxidase labeled goat anti-
mouse IgA, IgG, IgM (heavy and light chains; Kirkegaard & Perry Laboratories, 
Gaithersburg, MD) diluted 1:1000 in blocking solution 0.01 M PBS with 2% NFDM 
was added to each well. After incubation for 1 hour ± 15 minutes at 37oC and 
washing four times with 0.01 M PBS with 0.05% Tween 20, 0.1 mL of 3,3’,5,5’-
tetramethylbenzidine (TMB) substrate (Kirkegaard & Perry Laboratories, 
Gaithersburg, MD) was added to each well and the plate was incubated at room 
temperature for 10 minutes. The reaction was terminated after 10 minutes by adding 
100 µL sulfuric acid (2.5 M H2SO4) to each well prior to being examined for positive 
reactions. The plates were read with a SpectraMax spectrophotometer (Molecular 
Devices Inc., Sunnyvale, CA). Absorbance was measured at wavelengths 450 and 
650. Controls consisted of mouse serum that was collected from the mouse prior to 
splenectomy (positive) and ascites containing an unrelated Mab (negative). 
(ii) Sandwich ELISA. The BCA Protein Assay (Thermo Fisher Scientific 
Inc., Rockford, IL) was used to estimate the total protein of purified TcdA and the 
αCdA Bella-1. A titration of αCdA Bella-1 was analyzed by sandwich ELISA. Wells of 
an Immulon II high binding plate (Thermo Scientific, Waltham, MA) were coated with 
50 mg/ml and 81 mg/ml of TcdA specific polyclonal antibody diluted in carbonate 
buffer (pH 9.6). The plates were incubated for 1 hour ± 15 minutes at 37oC then 
washed four times with 0.01 M PBS with 0.05% Tween 20. The plates were then 
blocked for 1 hour ± 15 minutes at 37oC with blocking solution 0.01 M PBS with 2% 
NFDM. The antigen, TcdA, was then added to the plate diluted in 0.01 M PBS with 
2% NFDM. Ascites fluid was diluted starting at 1:100 to 1:30,000 in blocking solution 
then added to the plate and incubated for 1 hour ± 15 minutes at 37oC.  The plates 
were washed 4 times with 0.01 M PBS with 0.05% Tween 20 and 0.1 mL of affinity 
purified antibody peroxidase labeled goat anti-mouse IgA, IgG, IgM (heavy and light 
chains; Kirkegaard & Perry Laboratories, Gaithersburg, MD) diluted 1:1000 in 
blocking solution 0.01 M PBS with 2% NFDM was added to each well. After 
incubation for 1 hour ± 15 minutes at 37oC, the plates were washed four times with 
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0.01 M PBS with 0.05% Tween 20, then 0.1 mL of TMB substrate (Kirkegaard & 
Perry Laboratories, Gaithersburg, MD) was added to each well and the plate 
incubated at room temperature for 10 minutes. The reaction was terminated after 10 
minutes by adding 100 µL sulfuric acid (2.5 M H2SO4) to each well prior to being 
examined for positive reactions. The plates were read with a SpectraMax 
spectrophotometer (Molecular Devices Inc., Sunnyvale, CA). Absorbance was 
measured at wavelengths 450 and 650. Controls consisted of mouse serum that was 
collected from the mouse prior to splenectomy (positive) and ascites containing an 
unrelated Mab (negative).An additional sandwich ELISA was performed as 
described above using TcsH as the antigen. 
 
2.7 Neutralization assay. 
(i) TcdA LD50 dose. The toxicity of TcdA was determined by titrating 
TcdA in mice and calculating the 10LD50. Three mice were injected IV with 0.2mL of 
various dilutions of TcdA diluted in Bacto-Peptone diluent (10gm Bacto Peptone, 
2.5gm Sodium chloride per 1L).  
(ii) αCdA Bella-1. A neutralization assay was performed to check the 
neutralizing effect of the monoclonal antibody in-vivo. The TcdA was diluted to the 
10LD50 dose and αCdA Bella-1 was diluted 1:10, 1:20, 1:40, 1:80, 1:160 (protein 
concentration of 41.6 mg/mL). Each mixture was injected intravenously (0.2 mL 
dose) into 3 Swiss Webster mice (Harlan Sprague Dawley, Indianapolis, IN). The 
mice were observed for 72 hours and deaths were recorded. 
(iii) IRP 583. A toxin-antitoxin neutralization test was performed to check 
for the antitoxin units per mL (AU/mL) contained in IRP 583. TcdA was diluted to the 
10LD50 dose in Bacto-Peptone diluent (10gm Bacto Peptone, 2.5gm Sodium chloride 
per 1L). IRP 583 was diluted at various levels (1:10, 1:20, 1:40, 1:80, 1:160 and 
1:320) and 1.0 mL of diluted antibody was added to 0.8 mL of diluted TcdA and 0.2 
ml Bacto-Peptone diluent. The mixtures were allowed to neutralize for 1 hour at 
room temperature then placed on ice. Each mixture was injected intravenously (0.2 
mL dose) into 3 Swiss Webster mice (Harlan Sprague Dawley, Indianapolis, IN). The 
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mice were observed for 72 hours and deaths were recorded. Once the AU/mL in IRP 
583 was determined a toxin-antitoxin neutralization test was performed to check the 
neutralizing effect of the toxin A specific polyclonal antibody and determine the 10 Lo 
and L+ doses of TcdA. The 10Lo dose is defined as the greatest amount of toxin 
that, when mixed with 10 antitoxin units (AU), results in 100% survival of all mice 
inoculated intravenously with 0.2mL of the mixture. The 10L+ dose is defined as the 
least amount of toxin that, when mixed with 10 AU antitoxin, results in the death of 
80-100% of all mice.  
(iv) An additional mouse test was performed using crude C. difficile toxin to 
check for specificity to TcdA. The mouse test was run the same as the previous test 
with TcdA. 
 
2.8 SDS-PAGE and Western Blot. 
A western blot was done to check the specificity of the monoclonal antibody. 
TcdA, crude C. difficile toxin (VPI 10463) and crude C. sordellii toxin Strain #7502 
(TcsL +, TcsH -) and VPI 9048 (TcsL +, TcsH+) were all evaluated. Aliquots of each 
sample were mixed with 1X NuPAGE® LDS buffer (Invitrogen, Carlsbad, CA) and 
heated for 10 minutes at 70°C.   Tris acetate SDS running buffer (Invitrogen, 
Carlsbad, CA) was added to deionized water. The proteins were separated in 
duplicate NuPAGE® Tris-acetate 7% gels (Invitrogen, Carlsbad, CA) in Tris acetate 
SDS running buffer under reducing conditions.  A molecular weight calibration lane 
was loaded with Hi-Mark pre-stained molecular weight standards (Invitrogen, 
Carlsbad, CA). Gels were assembled into a sandwich with nitrocellulose membranes 
and transferred in an iBlot® Western Detection Kit (Invitrogen, Carlsbad, CA).  
Membranes were equilibrated in 20 mM Tris—500 mM NaCl (TBS, pH 7.5)  for 10 
minutes prior to being blocked in 20 mM Tris—500 mM NaCl—0.5% Tween 20 
(TTBS, pH 7.5) and incubated with agitation at room temperature for 30 to 60 
minutes. Membranes were then immersed in αCdA Bella-1 subclone supernatants 
C2 and C3 diluted to 1:100 in 20 mM Tris—500 mM NaCl—0.5% Tween 20 (TTBS, 
pH 7.5) and incubated with agitation at room temperature for 1 to 2 hours.  One 
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membrane was immersed in CPD IRP 578 (Clostridium perfringens Type D Mab) 
diluted 1:100 as a negative control and one membrane not immersed in a Mab, only 
in conjugate (neither pictured). Following four 10 minute washes in TTBS the 
membranes were immersed in affinity purified antibody peroxidase labeled goat anti-
mouse IgA, IgG, IgM (heavy and light chains; Kirkegaard & Perry Laboratories, 
Gaithersburg, MD) diluted 1:1000 and incubated with agitation at room temperature 
for 1 to 2 hours. After four 10 minute washes in TTBS, bound antibodies were 
detected with 3,3’,5,5’-tetramethylbenzidine (TMB) and TMB Membrane Enhancer 
(Kirkegarrd & Perry Laboratories, Gaithersburg, MD). 
Separated total protein of each sample was visualized by staining a duplicate 
nitrocellulose membrane with AuroDyeтм forte (GE Healthcare, Buckinghamshire, 
UK). 
 
2.9 Determination of isotype. 
Monoclonal antibody αCdA Bella-1 was tested using a Pierce® Rapid 
Isotyping kit (Thermo Fisher Scientific Inc., Rockford, IL).  
 
3. Results 
3.1 ELISA. 
Several hybridomas that reacted with purified TcdA were isolated. One of 
these, designated αCdA Bella-1, revealed a high sensitivity of the monoclonal 
antibody for the antigen TcdA, and reactivity extended to the 1/5000 dilution of 
ascites fluid. Similar results were obtained when using 81 or 53 mg/ml of IRP 583 as 
capture antibody (Figure 1). αCdA Bella-1 also showed sensitivity for the antigen 
TcsH with reactivity exceeding the 1/200 dilution of ascites fluid (Figure 2). 
 
3.2 Neutralization assay. 
The 10LD50 dose of the TcdA was 1:11 (protein concentration of 
approximately 5µg/mL). The monoclonal antibody was shown to neutralize TcdA and 
protect mice from 10 LD50 lethal effects at all dilutions tested (Table 1). The 
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polyclonal antiserum IRP 583 contained 160 AU/mL (Table 2). The Lo and L+ dose 
of purified TcdA was determined to be 0.5 ml and 0.7 ml, respectively (Table 3). The 
Lo dose of 0.5 mL was chosen to ensure 100% survival rate in the mice. The L+ 
dose of 0.7mL was the least amount of toxin that resulted in the death of 100% of all 
mice. The Pab was shown to be specific for TcdA when the mice injected with crude 
toxin, which contained lethal levels of TcdB, and various dilutions of Pab all died.  
 
3.3 SDS-PAGE and Western Blot. 
The monoclonal antibody αCdA Bella-1 subclone C2 and IRP 583 (Figure 3 
and 4) reacted with TcdA. There was also a slight reaction of αCdA Bella-1 subclone 
C2 and IRP 583 to the Bovine thyroglobulin in Lane 6, but this was also present with 
the conjugate only control (not shown). There was insufficient data to determine if 
αCdA Bella-1 subclone C2 and IRP 583 also detected TcsH because the TcsH band 
was not visible on the Western blot or the membrane blotted with Aurodye indicating 
that an insufficient amount of toxin may have been present in crude preparation to 
allow detection. 
 
3.4 Determination of isotype. 
The monoclonal antibody αCdA Bella-1 was shown to be of mouse IgG1, κ 
isotype. 
 
4. Discussion 
This study has shown the produced Mab, αCdA Bella-1 is specific for and 
neutralizes TcdA. It specifically recognized TcdA in Western Blotting and was shown 
to be protective in mice injected with the toxin. αCdA Bella-1 also reacted strongly to 
the TcdA and TcsH antigen in an indirect and sandwich ELISA. 
αCdA Bella-1did not cross react with TcsH on Western Blot. Previous work 
has shown that Mab’s for TcdA can cross react with TcsH [8]. This difference may 
be due to the different procedures used to purify the TcdA or a difference in the 
preparation of the toxoid that was used to immunize mice [8, 9]. DEAE-Sepharose 
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CL-6B columns with toxins A and B eluted by NaCl gradient as described by Sullivan 
et al [9] was used to produce a cross reacting Mab, unlike this study which used 
TcdA purified using bovine thyroglobulin. Although αCdA Bella-1did cross react to 
TcsH with the ELISA, it did not cross react with TcsH on the Western blot. The 
reason for this may be that the Mab is specific to a conformational epitope or was 
specific to an epitope that was blocked on Western Blot. This would explain why it 
reacts with the native toxin and not the de-natured toxin. 
The TcdA specific Pab (IRP 583) was also shown to neutralize TcdA in mice, 
it cross reacted with TcsH in ELISA and reacted with TcdA in western blot.  It was 
shown to be specific for TcdA since it would not protect mice against crude C. 
difficile supernatants containing both TcdA and TcdB. 
Clostridium difficile has recently emerged as a pathogen or commensal in 
food animals such as neonatal pigs and dairy and beef calves; most of these animal 
isolates are toxigenic [2]. Active or passive immunization against TcdA prevents 
clinical disease. Thus, it may be that if a toxin-neutralizing response can be 
generated in sows, piglets can be passively protected by antibodies obtained from 
colostrum [4]. Since it has been shown that antibodies to TcdA eliminate binding and 
prevent clinical disease in animal models; immunization against TcdA can prevent 
clinical disease [4]. C. difficile has also been found in retail meat and concerns about 
the role of food in the epidemiology of community-associated C. difficile infection 
(CA-CDI) have been expressed and due to the fact that C. difficile is gaining 
importance as an animal pathogen, there is now a potential for product licensing 
requests [3, 5]. Since αCdA Bella-1 has been shown to be specific and protective 
against TcdA it may be used as a reagent for product testing that is required by the 
CVB prior to licensure of new animal vaccines. 
 
5. Acknowledgements 
This work was supported by the Center for Veterinary Biologics Graduate 
Training Program. 
27 
 
Thank you to all the knowledgeable professional and technical staff in the 
Biologics Bacteriology section at the Center for Veterinary Biologics for all the 
assistance that was provided with this project.  
28 
 
References 
1. Anderson Michael A, Songer J. Glenn. Evaluation of two enzyme 
immunoassays for detection of Clostridium difficile toxins A and B in swine. 
Vet. Microbiol. 2008;128:204-206. 
 
2. Jhung Michael A, Thompson Angela D, Killgore George E, Zukowski Walter 
E, Songer Glenn, Warny Michael, Johnson Stuart, Gerding Dale N, McDonald 
L. Clifford and Limbago Brandi M. Toxinotype V Clostridium difficile in 
Humans and Food Animals. Emerg Infect Dis 2008;14:1039-1045. 
 
3. Pirs Tina, Ocepek Matjaz and Rupnik Maja. Isolation of Clostridium difficile 
from food animals in Slovenia. J Med Microbiol 2008;57:790-792. 
 
4. Songer J. Glenn and Anderson Michael A. Clostridium difficile: An important 
pathogen of food animals. Anaerobe 2006;12:1-4. 
 
5. Wees J. Scott, Avery Brent P, Rousseau J and Reid-Smith Richard J. 
Detection and Enumeration of Clostridium difficile  Spores in Retail Beef and 
Pork. Applied and Environmental Microbiology. 2009;75(15):5009-5011. 
 
6. Krivan Howard C and Wilkins Tracey D. Purification of Clostridium difficile 
Toxin A by Affinity Chromatography on Immobilized Thyroglobulin. Infect 
Immun. 1987;55(8):1873-1877. 
 
7. Van Deusen Richard A. in Hybridoma Technology in Agricultural and 
Veterinary Research, Totowa: Rowman and Allanheld, 1984, pp. 15–25. 
 
8. Martinez RD and Wilkins TD. 1992. Comparison of Clostridium sordellii toxins 
HT and LT with toxins A and B of C. difficile. J. Med. Microbiol. Vol. 36:30-36. 
 
9. Sullivan NM and Wilkins TD. 1982. Purification and Characterization of toxins 
A and B of Clostridium difficile. Infect. Immun. 35:1032-1040. 
 
  
29 
 
 
 
Figure 1 Sandwich ELISA Titration results for αCdA Bella-1using TcdA as the 
antigen. 
 
 
Figure 2. Sandwich ELISA titration results for αCdA Bella-1 using TcsH as the 
antigen. 
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Figure 3 Western Blot using the monoclonal antibody αCdA Bella-1 
subclone C2 
 
Figure 4 Western Blot using the Toxin A specific polyclonal antibody 
IRP 583  
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Figure 1 Western Blot using the monoclonal antibody αCdA Bella-1 subclone C2. 
Lane 1: Hi-Mark Protein ladder; Lane 2: Clostridium difficile purified Toxin A (VPI 
10463); Lane 3: Clostridium difficile crude toxin (VPI 10463); Lane 4: Clostridium 
sordellii purified Toxin HT (VPI 9048); Lane 5: Clostridium sordellii crude Toxin (VPI 
9048); Lane 6: Clostridium sordellii crude toxin (#7502). 
 
Figure 2 Western Blot using the Toxin A specific polyclonal antibody IRP 583. Lane 
1: Hi-Mark Protein ladder; Lane 2: Clostridium difficile purified Toxin A (VPI 10463); 
Lane 3: Clostridium difficile crude toxin (VPI 10463); Lane 4: Clostridium sordellii 
(VPI 9048); Lane 5: Clostridium sordellii crude Toxin (#7502); Lane 6: Bovine 
Thyroglobulin. 
  
32 
 
  
 
 
 
 
 
 
Table 1 Neutralization assay for αCdA Bella-1 against TcdA toxin 
 
 
 
 
 
 
 
 
Table 2 Neutralization assay to determine AU/ml in IRP 583 against TcdA toxin 
 
 
 
 
 
Table 3 Results from Neutralization assay for IRP 583 to determine Lo and L+ of TcdA. 
  
αCdA Bella-
1  Dilution 
No. 
dead/No. 
injected 
1:10 0/2 
1:20 0/2 
1:40 0/2 
1:80 0/2 
1:160 0/2 
IRP 583 
Dilution 
No. 
dead/No. 
injected 
1:10 0/2 
1:20 0/2 
1:40 0/2 
1:80 0/2 
1:160 0/2 
1:180 2/2 
TcdA 1:2.5 IRP 583 BP Diluent No. dead/No. injected 
0.5ml 1.0 ml/dil 1: 1:320        0.5ml 0/3 
0.6ml 1.0 ml/dil 1: 1:320        0.4ml 0/3 
0.7ml 1.0 ml/dil 1: 1:320        0.3ml 3/3 
0.8ml 1.0 ml/dil 1: 1:320        0.2ml 3/3 
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CHAPTER 3 GENERAL CONCLUSION 
Discussion 
In this study, the TcdA monoclonal antibody, αCdA Bella-1, and toxin A 
specific polyclonal antibody, IRP 583, were produced for use by the USDA-Center 
for Veterinary Biologics (CVB) in anticipation of vaccine product licensing requests. 
Specificity of both antibodies was determined using indirect enzyme-linked 
immunoabsorbent assay (ELISA), sandwich ELISA, western blot and toxin 
neutralization tests. Through these tests it was shown that both antibodies had 
specificity to TcdA. 
The monoclonal antibody, αCdA Bella-1 was then tested for specificity to 
TcsH by Western Blot, as well as, by sandwich ELISA since previous studies show 
that C. sordellii antitoxin cross-neutralizes TcdA and TcdB of C. difficile [1]. The 
results showed that αCdA Bella-reacted with TcsH in ELISA tests. 
αCdA Bella-1did not cross react with TcsH on Western Blot. Previous work 
has shown that Mab’s for TcdA can cross react with TcsH [8]. This difference may 
be due to the different procedures used to purify the TcdA or a difference in the 
preparation of the toxoid that was used to immunize mice [8, 9]. DEAE-Sepharose 
CL-6B columns with toxins A and B eluted by NaCl gradient as described by Sullivan 
et al [9] was used to produce a cross reacting Mab, unlike this study which used 
TcdA purified using bovine thyroglobulin. Although αCdA Bella-1did cross react to 
TcsH with the ELISA, it did not cross react with TcsH on the Western blot. The 
reason for this may be that the Mab is specific to a conformational epitope. This 
would explain why it reacts with the native toxin and not the de-natured toxin. 
 
 
Recommendations for future research 
It would be beneficial to obtain the gene sequence of Clostridium sordellii 
Toxin HT. Previous studies have shown that when immunizing guinea pigs with 
toxoid containing TcsL, TcsH and both TcsL/TcsH only the TcsL/TcsH toxoid gave 
complete protection against bacterial challenge with strains of C. sordellii. The result 
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shows that TcsL toxoid, as well as, TcsH toxoid are essential protective antigens of 
C. sordellii [2]. Obtaining the gene sequence would allow the development of a PCR 
assay method that could be used for the detection of TcsH in the bacterial strains 
that are used to produce vaccine products. If the TcsH gene is absent in the 
bacterial strains used it could then be deduced that the resulting vaccine product will 
not completely protect the animal against a C. sordellii infection because there would 
be a lack of TcsH antibody response. This research could result in a change to 
government regulations relating to vaccine products containing C. sordellii toxoid. 
  
35 
 
References 
1. Martinez RD and Wilkins TD. 1992. Comparison of Clostridium sordellii toxins 
HT and LT with toxins A and B of C. difficile. J. Med. Micrbiol. Vol. 36:30-36. 
 
2. Katsuhiko A, Eiji O, Hisao Y, Osamu S, Shigeji K, Takashi K, Akihiro I, and 
Tadashi H. 2001. Protective Effects of Clostridium sordellii LT and HT 
Toxoids against Challenge with Spores in Guinea Pigs. J. Vet. Med. Sci. 
63(8): 879-883. 
  
36 
 
APPENDIX A. CLOSTRIDIUM SORDELLII HEMORRHAGIC TOXIN (TcsH) 
SEQUENCING 
 
1. Procedures performed in an attempt to sequence C. sordellii Toxin HT 
(TcsH) 
1.1 Polymerase Chain reaction (PCR) 
Since the biological and antigenic properties of TcdA and TcdB are very 
similar to those of TcsH and TcsL and C. sordellii antitoxin cross-neutralizes TcdA 
and TcdB it is suggested the two toxins of C. sordellii are immunologically related to 
the C. difficile toxins [1, 2]. A published PCR protocol for C. difficile was used to 
attempt to get the TcsH sequence by using primers that were specific for TcdA [3]. 
The annealing temperature was reduced in an attempt to get the primers to bind 
even if several of the base pairs were mismatched. The annealing temperature 
ranged from 38 to 55°C. PCR products were run using g el electrophoresis. When 
bands were visible that looked equivalent to the 600bp band for TcdA they were cut 
out of the gel and DNA was extracted from the bands using the MinElute PCR 
Purification Kit (Qiagen, Valencia, CA).  Once the DNA was extracted a TOPO TA 
Cloning® Kit (Invitrogen, Carlsbad, CA) was used and the resulting transformants 
were sent to the Iowa State University (ISU) DNA facility for sequencing. 
 
1.2 Isoelectric focusing 
It has been previously shown that TcsH has an isoelectric point (pI) of 6.10 
[4]. Crude toxin was made from C. sordellii Strain VPI 9048. The resulting toxin was 
concentrated 10X using iCON™ concentrators from Pierce Scientific. The 
concentrated toxin was then isoelectric focused using a Biorad Rotofor™ 
Preparative IF cell (Biorad Laboratories Inc., Hercules, CA). SDS-PAGE was then 
performed on the sample that resulted in a pI closest to 6.10. The gel was then 
blotted onto a nitrocellulose membrane and stained with Aurodye™ Forte (GE 
Healthcare) and the resulting bands were analyzed. 
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1.3 Southern Blot 
Previous research has shown that when running a Southern Blot using a 
TcdA specific probe C. sordellii strains will also show positive hybridization provided 
that the C. sordellii strains were positive on the TcdA and TcdB assays [5]. A 
published PCR protocol for TcdA was performed. The resulting gel was used to 
extract and purify DNA using a S.N.A.P™ Gel Purification Kit (Invitrogen, Carlsbad, 
CA) [3]. Once TcdA specific DNA was obtained it was labeled using a DIG High 
Prime DNA Labeling and Detection Starter Kit (Roche Diagnostics Corp, 
Indianapolis, IN).  The restriction endonuclease Hind III was used to digest C. 
sordellii genomic DNA. The resulting gel was used for the Southern Blot and the C. 
difficile Toxin A probe was used for immunological detection. 
 
1.4 Affinity Chromatography 
The Mab αCdA Bella-1was coupled to AminoLink® Coupling gel (Thermo 
Fisher Scientific Inc., Rockford, IL) and affinity chromatography was used to purify 
TcsH as previously described [4]. The resulting eluate was run on a SDS-PAGE gel 
and blotted onto a nitrocellulose membrane. To determine if TcsH was present the 
membrane was stained using Aurodye™ Forte (GE Healthcare) and Coomassie 
stain. The resulting bands will be sent to the ISU Protein Facility and the protein 
sequence of TcsH can be obtained. 
 
1.5 Subtractive Hybridization 
Subtractive hybridization methods can be used to identify cDNA sequences 
that are present in one bacterial genome, but absent in another. The genomic DNA 
that contains the genes of interest is considered the tester and the reference sample 
is considered the driver. Tester and driver DNAs are hybridized and the hybrid 
sequences are removed. The remaining unhybridized DNAs represent genes that 
are expressed in the tester yet are absent in the driver. Using the Clontech PCR-
Select™ Bacterial Genomic Subtraction Kit (ClonTech Laboratories Inc., Mountain 
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View, CA) as recommended by suppliers, a TcsH – strain #7502 was used as the 
driver and a TcsH + strain VPI 9048 was used as the tester. 
 
1.6 Primer Walking 
The whole genome for C. difficile strain 630 has been sequenced (GenBank 
accession AM180355). The location of the TcdB gene is from base 787,393 to 
794,493 and the TcdA gene is from base 795843 to 803975. This shows that the two 
genes are only located 1350 bases apart. Assuming that TcsL and TcsH would be 
located a similar distance apart C. sordellii DNA was submitted to the ISU DNA 
facility for primer walking. A primer was designed from the published TcsL sequence 
(GenBank accession X82638) and primer walking to the TcsH gene was attempted. 
 
2. Results from procedures performed in an attempt to sequence C. 
sordellii Toxin HT (TcsH) 
 
2.1 Polymerase Chain reaction (PCR) 
When the resulting PCR products were run on the E-gels (Invitrogen, 
Carlsbad, CA) bands that were approximately the same size as the TcdA band were 
present (Figure A.1 – A.3). When the PCR products were purified, inserted into a 
plasmid and sent to ISU for sequencing the results did not match TcdA when 
nucleotide BLAST was used to analyze them. 
 
2.2 Isoelectric focusing 
Isoelectric focusing showed a pI of 6.18. SDS-PAGE was run using this 
sample and blotted to a membrane. When stained with Aurodye TcsH migrated as a 
band with the molecular weight of approximately 300,000 kDa (Figure A.4). 
Unfortunately, I was unable to submit the band for sequencing to the ISU Protein 
Facility due to the fact that the Coomassie stain didn’t produce a visible band and 
the faint Aurodye band couldn’t be used for sequencing either.  
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2.3 Southern Blot 
Hind III was successful in cutting C. sordellii VPI 9048 DNA (Figure A.5), but 
no bands were present after running the Southern Blot. After several tries I was 
unable to get any bands; which I believe was due to insufficient concentration of the 
C. difficile probe. 
 
2.4 Affinity Chromatography 
SDS-PAGE of the resulting eluate migrated as a band with the molecular 
weight of approximately 300,000 kDa (Figure A.6, A.7). The band was visible using 
Aurodye stain, not visible using Coomassie stain so I was unable to submit the band 
to the ISU Protein Facility even after several additional attempts to concentrate it 
further. 
 
2.5 Subtractive Hybridization 
The restriction enzyme, Rsa I, was successful in cutting both C. difficile and 
C. sordellii DNA (Figure A.7). Adaptors were then ligated onto the cut DNA and the 
final hybridization step was performed (Figure A.8).The hybridization step was 
unsuccessful in showing any genes of interest that may have been present in the 
Tester, but not the Driver. 
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Figure A.1 E-gel results from PCR Thermocyler run with 55°C anne aling temperature. Lane 
1: 1 KB Plus TrackIt DNA ladder ; Lane 2: Clostridium difficile VPI 10463 (2.5µl); Lane 3: 
Clostridium difficile VPI 10463 (5µl); Lane 4: Clostridium sordellii VPI 9048 (2.5 µl); Lane 5: 
Clostridium sordellii VPI 9048 (2.5µl); Lane 6: Clostridium sordellii VPI 9048 (1µl); Lane 7: 
Clostridium sordellii VPI 9048 (5µl); Lane 8: Negative Control; Lane 9: 1 KB Plus TrackIt 
DNA ladder. 
 
 
 
Figure A.2 E-gel results from PCR Thermocyler run with 45°C anne aling temperature. Lane 
1: 1 KB Plus TrackIt DNA ladder ; Lane 2: Clostridium difficile VPI 10463 (2.5µl); Lane 3: 
Clostridium difficile VPI 10463 (5µl); Lane 4: Clostridium sordellii VPI 9048 (2.5 µl); Lane 5: 
Clostridium sordellii VPI 9048 (2.5µl); Lane 6: Clostridium sordellii VPI 9048 (1µl); Lane 7: 
Clostridium sordellii VPI 9048 (5µl); Lane 8: Negative Control; Lane 9: 1 KB Plus TrackIt 
DNA ladder. 
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Figure A.3 E-gel results from PCR Thermocyler run with 38°C anne aling temperature. Lane 
1: 1 KB Plus TrackIt DNA ladder ; Lane 2: Clostridium difficile VPI 10463 (2.5µl); Lane 3: 
Clostridium difficile VPI 10463 (5µl); Lane 4: Clostridium sordellii VPI 9048 (2.5 µl); Lane 5: 
Clostridium sordellii VPI 9048 (2.5µl); Lane 6: Clostridium sordellii VPI 9048 (1µl); Lane 7: 
Clostridium sordellii VPI 9048 (5µl); Lane 8: Negative Control; Lane 9: 1 KB Plus TrackIt 
DNA ladder. 
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Figure A.4 Aurodye Blot results for Isoelectric focused samples. Lane 1: C. difficile crude 
toxin VPI 10463. Lane 2: C. sordellii VPI 9048 isoelectric focused sample 1, Lane 3: C. 
sordellii VPI 9048 isoelectric focused sample 2, Lane 4 C. sordellii VPI 9048 isoelectric 
focused sample 3,  Lane 5: Hi-Mark Protein ladder. 
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Figure A.5 REA gel used for Southern Blot procedure. Lane 1: λ Hind III Ladder, Lane 2: C. 
difficile VPI 10463 cut with Hind III, Lane 3 C. sordellii VPI 9048 cut with Hind III, Lane 4: λ 
Hind III Ladder. 
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Figure A.6 Affinity Chromatography results. Lane 1: Hi-Mark Protein ladder, Lane 2: C. 
difficile VPI 10463, Lane 2 Concentrated C. difficile VPI 10463 Lane 3: C. sordellii TcsH, 
Lane 4: C. sordellii TcsH, Lane 5: Hi-Mark Protein ladder.  
  
Figure A.7 REA gel from Subtractive Hybridization kit. Lane 1: 1 KB Plus TrackIt DNA 
ladder, Lane 2: C. sordellii VPI 9048 cut with Rsa I, Lane 3: C. sordellii 7502 cut with Rsa I, 
Lane 4: Control DNA (Escherichia coli) cut with Rsa I, Lane 5: 1 KB Plus TrackIt DNA 
ladder.  
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Figure A.8 Hybridization gel from Subtractive Hybridization kit. Lane 1: 1 KB Plus TrackIt 
DNA ladder, Lane 2: Subtracted experimental DNA, Lane 3: Un-subtracted tester control, 
Lane 4: Subtracted control DNA form E. coli, Lane 5: Un-subtracted tester control for the 
control subtraction Lane 6: PCR control subtracted DNA, Lane 7: 1 KB Plus TrackIt DNA 
ladder. 
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